‘Get interventions to market – and to people – faster and cheaper’

Longevitytech.fund’s Petr Sramek on why the longevity field needs to look at the whole – and why it needs precision and personalization.

Leading longevity investor Petr Sramek has been a serial entrepreneur for more than 33 years. Currently Managing Partner at VC Longevitytech.fund, he is also CEO of Healthy Longevity Clinic and a board member at Biotech.

My take on this: Longevitytech.fund has invested in 44 companies – this means Sramek is ideally placed to have his finger on the pulse of longevity. We caught up with Sramek to find out about his journey with Longevitytech.fund and what longevity now and longevity next looks like at Healthy Longevity Clinic – and what his latest biological age test revealed…

Petr Sramek on 'time for the bigger picture'

I founded Longevitytech.fund four years ago, and during that journey, I have had experience of talking to hundreds of scientists and various companies, actually investing in 44 of those companies. This journey has given me a unique perspective on what we actually need in the space and what we need for in order to provide significant expansion of healthspan.

Everyone is working on something specific – telomere extension, killing senescent cells, improving whatever pathway – but no-one is really looking at the whole. And it’s not just a holistic approach – it’s combining it with precision and personalized medicine.

We built the portfolio of Longevitytech.fund companies in a unique way, creating a blend of various technologies, not just across biological pathways, but also across the timeline, so we’ll get access to short-term, mid-term and even long-term solutions. It’s a long route to the market for these interventions, especially because of various regulatory approval requirements.

My latest TruAge methylation measurement showed my biological age is 16 years below my chronological age. I’m 55 chronologically, but I got a score of 39, which was surprising because I got -6 18 months ago, so I didn’t expect such an improvement. But I’m on top of everything we do at the clinic – and I’m kind of a guinea pig for some of these interventions. But it’s additional proof that the clinic can deliver.

Gain comprehensive insights into clinical trial conduct, collaborating with portfolio companies, sharing knowledge and expanding globally with Petr Sramek HERE.

Thank you for reading! If you enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!